Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xyrem ® (sodium oxybate) Xywav contains 92% less sodium per nightly dose than sodium oxybate DUBLIN, June 25, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Xywav is an oxybate product with a unique composition of cations resulting in 92% less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.1 FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or EDS associated with narcolepsy, stating that "the active moiety, oxybate, was previously approved as Xyrem® (sodium oxybate) for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 1 Somewhat Bullish 1 1 0 0 Indifferent 0 0 0 1 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Jazz Pharmaceuticals. The company has an average price target of $214.78 with a high of $250.00 and a low of $176.00.

Where Jazz Pharmaceuticals Stands With Analysts

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has updated its full-year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company acquired on May 5. Forecasts total net product sales of 3 billion to $3.1 billion in line with the consensus of $3.1 billion, compared to the earlier outlook of $2.5 billion - $2.7 billion.

Jazz Pharmaceuticals Updates 2021 Guidance To Include GW Pharma Acquisition

DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company acquired on May 5, 2021. "We expect 2021 to be another exciting, productive and transformational year for Jazz and are pleased to update our guidance to include the addition of GW.

Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc

2 Marijuana Stocks To Add To Your Watchlist In June The post 2 Marijuana Stock To Add To Your Watchlist This Week appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stock To Add To Your Watchlist This Week

Autohome

SEI Investments

Toro

AMERCO

According to the GuruFocus discounted cash flow calculator as of June 16, the following companies have a high margin of safety and have grown their margins over a 10-year period.

5 Fast-Growing Stocks In Gurus' Portfolios

Arch Capital

Markel

If screening the market for value opportunities, investors may want to consider the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow (DCF) calculator.

These 3 Stock Picks Seem to Be Underestimated by the Market

Anthem

Cooper Companies

Emergent BioSolutions

Humana

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned defensive companies have grown their book value per share over the past decade through June 14.

5 Defensive Stocks Trading With Low Book Value

DUBLIN, June 14, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed with consultation from leading cancer organizations CancerCare, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America and LUNGevity Foundation. Nothing Small About It is the first digital hub for U.S. audiences dedicated solely to small cell lung cancer (SCLC) patients and caregivers, and it provides user-friendly content that puts real people and their stories at the center of the experience, enabling those living with SCLC to become informed advocates in their health and well-being.

Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community

DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021. "Jazz continues to be committed to deepening our understanding of sleep disorders and delivering transformational medicines to those with lifelong and chronic sleep conditions," said Robert Iannone, M.D.

Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021

GW Pharmaceuticals

NEW YORK, June 4, 2021 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of California, Ziegler v. GW Pharmaceuticals, PLC et al, Docket No.

Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of GW Pharmaceuticals, PLC In The Southern District Of California

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Why Is Jazz (JAZZ) Up 1.8% Since Last Earnings Report?

AbbVie

2 Biotech Cannabis Stocks To Watch Next Month As marijuana stocks continue… The post 2 Biotech Cannabis Stocks To Watch In June 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Biotech Cannabis Stocks To Watch In June 2021

DUBLIN, May 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 1:00 p.m. ET / 6:00 p.m.

Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021

AdvisorShares Pure US Cannabis ETF

These Could Be Cannabis Investments For Your Long Term Portfolio The post The Best Long Term Cannabis Stocks Right Now? 2 For To Watch In May appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

The Best Long Term Cannabis Stocks Right Now? 2 For To Watch In May

DUBLIN, May 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021 and five abstracts at the virtual 26th Annual Congress of the European Hematology Association (EHA2021) from June 9 –16, 2021. Research findings to be presented include new data on Zepzelca ®  (lurbinectedin), Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 (formerly known as CPX-351), and Defitelio® (defibrotide sodium).

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

This neurobiology specialist just completed the acquisition of GW Pharma and this bolsters their pipeline diversity and strength. Xywav is set up to pick up the majority of the ending Xyrem revenues and maintain the company's forward momentum.

Jazz Pharmaceuticals: Undervalued Even Before GW Acquisition Kicks In

Aurora Cannabis

Curaleaf Holdings, Inc.

GrowGeneration Corp

SNDL Inc.

Trulieve Cannabis Corp.

And ignoring it could cost you significant returns.

Warren Buffett Has a Warning for Growth Investors

Arena Pharmaceuticals

HEXO Corp

FSD Pharma

Innovative Industrial Properties

OrganiGram Holdings Inc.

Tilray Brands

22nd Century Group

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in 2021.

What Happened with Marijuana Stocks This Week?

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH).

Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio

Jazz (JAZZ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Jazz (JAZZ): Can Its 6.6% Jump Turn into More Strength?

The developer of cannabis-based medications is now under new ownership.

Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes

Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down

Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down

DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q1 2021 Results - Earnings Call Transcript

News for Jazz Pharmaceuticals Stock (JAZZ)